⚖️ US Supreme Court to Hear Major ‘Skinny Label’ Patent Dispute
The U.S. Supreme Court has agreed to take up a closely watched pharmaceutical patent case involving Amarin Pharma’s cardiovascular drug, Vascepa—a decision that could have wide-ranging consequences for generic drug makers and FDA labeling practices.
At the core of the dispute is the use of “skinny labels,” which allow generic manufacturers to enter the market by excluding patented uses from their product labels. While this approach is meant to encourage competition, Amarin argues that generic manufacturer Hikma crossed the line by encouraging doctors to prescribe its generic version for patented indications.
In 2024, the U.S. Court of Appeals for the Federal Circuit revived Amarin’s lawsuit, citing Hikma’s public statements—such as referring to its product as “generic Vascepa”—as potentially encouraging infringing prescriptions. Hikma contends that this interpretation threatens the very purpose of skinny labels and could discourage generic competition.
💊 With Vascepa generating over $228 million in revenue in 2024, the outcome of this case carries significant financial and legal weight. The Supreme Court’s decision may reshape pharmaceutical patent enforcement, FDA labeling strategies, and access to affordable generic medicines.
📌 Ultimately, the ruling could redefine the balance between protecting pharmaceutical innovation and promoting market competition in the life sciences sector.
📌 Contact IP Consulting Group for free, tailored IP insights and legal guidance 📧 [email protected] 🌐 www.ipconsultinggroups.com